Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Juan Zeng,Heying Zhang,Yi Tan,Zhe Wang,Yunwei Li,Xiaoguang Yang

DOI: https://doi.org/10.6084/m9.figshare.15086087

2021-01-01

Abstract:Additional file 1. Antibodies for WB and primers for RT-qPCR used in this study.

What problem does this paper attempt to address?

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

Wan-Xin Peng,Liu Yang,Yin-Yuan Mo

DOI: https://doi.org/10.1158/1538-7445.am2020-4827

IF: 11.2

2020-01-01

Cancer Research

Abstract:N6-methyladenosine (m6A) is one of the most prevalent modifications of mRNAs in eukaryotes. Numerous recent studies have indicated that m6A plays the critical role in multiple physiologic functions and disease processes by regulation of mRNA processing, splicing, translation, and stability. Although the majority of RNA methylation studies focus on mRNAs, little is known whether long-coding RNAs (lncRNAs) are also subject to m6A modification. Therefore, this study aims to identify m6A modified lncRNAs and their functional role in pancreatic cancer. We performed methylated RNA immunoprecipitation (MeRIP) profiling against a focused group of lncRNAs and identified five lncRNA candidates, among which the highly enriched lncRNA was LINC00901. RNA dot blot, m6A RNA methylation quantification detection and in vivo RNA pulldown combined with m6A RNA methylation Western Blot confirmed the m6A modification of LINC00901. Of note, the analysis of TCGA datasets indicated that the high level of LINC00901 is associated with the poor overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients. Consistent with this result, we showed that LINC00901 promotes pancreatic cancer cell growth. Importantly, we identified that YTHDF1 serves as a “reader” of the m6A modified LINC00901 and furthermore, ectopic expression of YTHDF1 causes downregulation of LINC00901, suggesting a role for m6A modification in regulation of LINC00901 expression. Experiments are underway to determine how LINC00901 promotes pancreatic cancer cell growth. Citation Format: Wan-Xin Peng, Liu Yang, Yin-Yuan Mo. N6-Methyladenosine modification of LINC00901 promotes pancreatic cancer progression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4827.
A Prognostic Model of M6a-Related Lipid Metabolism-Associated Genes in Pancreatic Adenocarcinoma

Xing Huang,Mao Li,Zihe Wang,Zuowei Wu,Shengzhong Hou,Bole Tian,Yi Zhang

DOI: https://doi.org/10.2139/ssrn.3904910

2021-01-01

SSRN Electronic Journal

Abstract:Background: N6-methyladenosine (m6A) genes and lipid metabolism-associated genes (LMAGs) play vital roles in the tumorigenesis of pancreatic adenocarcinoma (PAAD) and have prognostic value. Thus, the identification of LMAGs associated with m6A in PAAD patients is critical. Methods: Based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases (n=349), m6A-related LMAGs were obtained by coexpression analysis. A prognostic model was constructed by using the multivariate Cox regression method and validated in a dataset from the Gene Expression Omnibus (GEO) database (n = 69). Functional enrichment annotation, Kaplan-Meier analysis and principal component analysis (PCA) were used to analyse the prognostic model, and the immune microenvironment and chemotherapy response were evaluated. We performed untargeted metabolomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in tissue and serum from 10 patients with PAAD and 10 patients with benign pancreatic diseases. Finding: m6A-related LMAGs were primarily associated with the arachidonic acid and glycerophospholipid metabolism pathways. The prognostic model was constructed based on PTGES, TSPOAP1, INPP4B and HSD17B14. Low risk scores were associated with a better prognosis, a higher immune status, and greater sensitivity to 5-fluorouracil. The untargeted metabolomics results also revealed significant remodelling of lipid metabolism, especially eicosanoid and glycerophospholipid metabolism. Interpretation: This study revealed the important role of m6A modification in lipid metabolism. The risk model based on m6A-related LMAGs may be promising for the clinical prediction of prognosis and therapy in PAAD patients. \Funding: Sichuan Science and Technology Program(2021YFS0234)Declaration of Interest: The authors declare that they have no conflicts of interest.Ethical Approval: This study was approved by the Biomedical Research Ethics Committee, WestChina Hospital of Sichuan University.
Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival

Yan Geng,Renguo Guan,Weifeng Hong,Bowen Huang,Peizhen Liu,Xiaohua Guo,Shixiong Hu,Min Yu,Baohua Hou

DOI: https://doi.org/10.21037/atm.2020.03.98

IF: 3.616

2020-03-01

Annals of Translational Medicine

Abstract:BACKGROUND: N6-methyladenosine (m6A) modification holds an important position in tumorigenesis and metastasis because it can change gene expression and even function in multiple levels including RNA splicing, stability, translocation and translation. In present study, we aim to conducted comprehensive investigation on m6A RNA methylation regulators and m6A-related genes in pancreatic cancer and their association with survival time.METHODS: Based on Univariate Cox regression analysis, protein-protein interaction analysis, LASSO Cox regression, a risk prognostic model, STRING, Spearman and consensus clustering analysis, data from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) database was used to analyze 15 m6A RNA methylation regulators that were widely reported and 1,393 m6A-related genes in m6Avar.RESULTS: We found that 283 candidate m6A RNA methylation-related genes and 4 m6A RNA methylation regulatory factors, including RNA binding motif protein 15 (RBM15), methyltransferase like 14 (METTL14), fat mass and obesity-associated protein (FTO), and α-ketoglutarate-dependent dioxygenase AlkB homolog 5 (ALKBH5), differed significantly among different stages of the American Joint Committee on Cancer (AJCC) staging system. Protein-protein interaction analysis indicated epidermal growth factor receptor (EGFR), plectin-1 (PLEC), BLM RecQ like helicase (BLM), and polo like kinase 1 (PLK1) were closely related to other genes and could be considered as hub genes in the network. The results of LASSO Cox regression and the risk prognostic model indicated that AJCC stage, stage T and N, KRAS mutation status and x8q23.3 CNV fragment mutation differed significantly between the high-risk and the low-risk subgroups. The AUCs of 1 to 5 years after surgery were all more than 0.7 and increased year by year. Finally, we found KRAS mutation status and AJCC stage differed significantly among these groups after TCGA samples divided into subgroups with k=7. Moreover, we identified four m6A RNA methylation related genes expressed significantly differently among these seven subgroups, including collagen type VII alpha 1 chain (COL7A1), branched chain amino acid transaminase 1 (BCAT1), zinc finger protein 596 (ZNF596), and PLK1.CONCLUSIONS: Our study systematically analyzed the m6A RNA methylation related genes, including expression, protein-protein interaction, potential function, and prognostic value and provides important clues to further research on the function of RNA m6A methylation and its related genes in pancreatic cancer.

oncology,medicine, research & experimental
Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer

Yongdong Guo,Ronglin Wang,Junqiang Li,Yang Song,Jie Min,Ting Zhao,Lei Hua,Jingjie Shi,Chao Zhang,Peixiang Ma,Cheng Yang,Liaoliao Zhu,Dongxue Gan,Shanshan Li,Xiaonan Liu,Haichuan Su

DOI: https://doi.org/10.3389/fimmu.2021.769425

2021-11-05

Abstract:Pancreatic cancer (PAAD) is one of the most malignant cancers and immune microenvironment has been proved to be involved in pathogenesis of PAAD. m6A modification, related to the expression of m6A regulators, participates in the development of multiple cancers. However, the correlation between m6A regulators and immune microenvironment was largely unknown in PAAD. And because of the small sample size of pancreatic cancer in the TCGA database, it is not enough to draw a convincing conclusion. In the present study, we downloaded seven pancreatic cancer datasets with survival data and removed batch effects among these datasets to be used as the PAAD cohort to analyze the immune landscape of PAAD and the expression pattern of m6A regulators and divided the integrated dataset into cluster 1 and cluster 2 by consensus clustering for m6A regulators. Lower m6A regulators were found to be related to higher immune cell infiltration and a better survival. Moreover, we identified six m6A regulators and constructed the prognostic signature of m6A regulators. Patients with low-risk score had a higher response to immune checkpoint inhibitor and a longer overall survival. To figure out the underlying mechanism, we analyzed the cancer immunity cycle, most altered genes, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) in risk subtypes. In summary, the present study proved m6A regulators modulated the PAAD immune microenvironment. And risk scores served as predictive indicator for immunotherapy and played a prognostic role for PAAD patients. Our study provided novel therapeutic targets to improve immunotherapy efficacy.
The Potential Value of M6a RNA Methylation in the Development of Cancers Focus on Malignant Glioma

Fan Chen,Xuan Xie,Min Chao,Haiyan Cao,Liang Wang

DOI: https://doi.org/10.3389/fimmu.2022.917153

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:N6-methyladenosine (m6A) RNA methylation is an epigenetic modification that has emerged in the last few years and has received increasing attention as the most abundant internal RNA modification in eukaryotic cells. m6A modifications affect multiple aspects of RNA metabolism, and m6A methylation has been shown to play a critical role in the progression of multiple cancers through a variety of mechanisms. This review summarizes the mechanisms by which m6A RNA methylation induced peripheral cancer cell progression and its potential role in the infiltration of immune cell of the glioblastoma microenvironment and novel immunotherapy. Assessing the pattern of m6A modification in glioblastoma will contribute to improving our understanding of microenvironmental infiltration and novel immunotherapies, and help in developing immunotherapeutic strategies.
m<SUP>6</SUP>A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer

Kaili Liao,Jialing Hu,Yu Huang,Siji Yu,Qijun Yang,Fan Sun,Chengfeng Wu,Yunqi Cheng,Wenyige Zhang,Xue Zhang,Hongyu Li,Xiaozhong Wang

DOI: https://doi.org/10.3389/fonc.2022.879405

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:BackgroundPrevious studies reported the related role of RNA n6-methyladenosine (m6A) modification in tumorigenesis and development. However, it is not clear whether m6A modification also plays a potential role in the immune regulation of rectal cancer (RC) and the formation of tumor microenvironment. MethodsIn this study, we screened 23 m6A regulatory factors from 369 rectal cancer specimens, further determined the modification patterns of m6A in RC, and systematically linked these modification patterns with the characteristics of TME cell infiltration. The principal component analysis (PCA) algorithm was used to evaluate the m6A modification pattern of a single tumor related to immune response. ResultsThree different m6A modification patterns were found in the measurement results, which are related to different clinical results and biological pathways. TME identification results show that the identified m6A pattern is closely related to immune characteristics. According to the m6Ascore extracted from m6A-related signature genes, RC patients were divided into high and low score subgroups combined with tumor mutation burden. Patients with high tumor mutation burden and higher m6Ascore have a significant survival advantage and enhanced immune infiltration. Further analysis showed that patients with higher m6Ascore had higher PD-L1 expression levels and showed better immune response and lasting clinical benefits. ConclusionsM6A modification plays a crucial role in the formation of TME diversity and complexity. The evaluation of the m6A modification mode will help us to enhance our understanding of the characteristics of TME infiltration and provide new insights for more effective immunotherapy strategies.
Characterization of Modification Patterns, Biological Function, Clinical Implication, and Immune Microenvironment Association of m6A Regulators in Pancreatic Cancer

Kun Fang,Hairong Qu,Jiapei Wang,Desheng Tang,Changsheng Yan,Jiamin Ma,Lei Gao

DOI: https://doi.org/10.3389/fgene.2021.702072

IF: 3.7

2021-09-17

Frontiers in Genetics

Abstract:Objective: N 6 -methyladenosine (m 6 A) modification may modulate various biological processes. Nonetheless, clinical implications of m 6 A modification in pancreatic cancer are undefined. Herein, this study comprehensively characterized the m 6 A modification patterns in pancreatic cancer based on m 6 A regulators. Methods: Genetic mutation and expression pattern of 21 m 6 A regulators and their correlations were assessed in pancreatic cancer from TCGA dataset. m 6 A modification patterns were clustered using unsupervised clustering analysis in TCGA and ICGC datasets. Differences in survival, biological functions and immune cell infiltrations were assessed between modification patterns. A m 6 A scoring system was developed by principal component analysis. Genetic mutations and TIDE scores were compared between high and low m 6 A score groups. Results: ZC3H13 (11%), RBM15B (9%), YTHDF1 (8%), and YTHDC1 (6%) frequently occurred mutations among m 6 A regulators. Also, most of regulators were distinctly dysregulated in pancreatic cancer. There were tight crosslinks between regulators. Two m 6 A modification patterns were constructed, with distinct prognoses, immune cell infiltration and biological functions. Furthermore, we quantified m 6 A score in each sample. High m 6 A scores indicated undesirable clinical outcomes. There were more frequent mutations in high m 6 A score samples. Lower TIDE score was found in high m 6 A score group, with AUC = 0.61, indicating that m 6 A scores might be used for predicting the response to immunotherapy. Conclusion: Collectively, these data demonstrated that m 6 A modification participates pancreatic cancer progress and ornaments immune microenvironment, providing an insight into pancreatic cancer pathogenesis and facilitating precision medicine development.

genetics & heredity
The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Shuiping Liu,Qiujie Li,Ke Chen,Qin Zhang,Guohua Li,Lvjia Zhuo,Bingtao Zhai,Xinbing Sui,Xiaotong Hu,Tian Xie

DOI: https://doi.org/10.1016/j.biopha.2020.110098

IF: 7.419

2020-01-01

Biomedicine & Pharmacotherapy

Abstract:N6-methyladenosine (m6A) is the most abundant RNA modification; m6A modifications are installed by methyltransferases, removed by demethylases and recognized by reader proteins. M6A plays crucial roles in a variety of biological processes by regulating target RNA translation, splicing, nuclear export, and decay. Since the establishment of methylated RNA immunoprecipitation-sequencing methodology, over three hundred articles about m6A modulators, including "writers", "erasers" and "readers", have been reported in the last four years. In addition, an increasing number of molecular mechanisms underlying m6A RNA methylation in human cancers have been comprehensively clarified. The recently emerged molecular mechanisms of m6A modulators in cancer cell proliferation, cell cycle progression, migration and invasion, apoptosis, and autophagy remain to be summarized. Hence, this review specifically summarizes these recent advances in the understanding of m6A molecular mechanisms in tumorigenesis and cancer progression. In addition, we discuss the prospect of using an m6A methylation modulator as a new diagnostic biomarker and therapeutic target for human cancers.
The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma

Rong Tang,Yiyin Zhang,Chen Liang,Jin Xu,Qingcai Meng,Jie Hua,Jiang Liu,Bo Zhang,Xianjun Yu,Si Shi

DOI: https://doi.org/10.7717/peerj.9602

IF: 3.061

2020-01-01

PeerJ

Abstract:Background. Pancreatic adenocarcinoma (PAAD) is among the most lethal diseases and has a dismal prognosis; however, efficient treatment is currently limited. Several studies have observed epigenetic variation during tumorigenesis, suggesting the potential role of RNA methylation, especially N6-methyladenosine (m6A) modification, as a novel epigenetic modification mediating PAAD prognosis. Methods. The expression levels of m6A-related genes were downloaded from The Cancer Genome Atlas-Pancreatic Adenocarcinoma (TCGA) and Genotype-Tissue Expression (GTEx) projects, and the findings were validated in four Expression Omnibus (GEO) datasets. A predictive model was constructed using a lasso regression and evaluated by a survival analysis and receiver operating characteristic curve. Consensus clustering identified two distinct subgroups with different immune activity signatures based on the expression pattern of m6A-related genes. The relationship between the mutation state of m6A-related genes and infiltration of immune cells was established and visualized using Tumor Immune Estimation Resource (https://cistrome.shinyapps.io/timer/). Results. Fourteen of twenty-one m6A-related genes were differentially expressed between PAAD and normal tissues in TCGA-GTEx cohort. Among these genes, HNRNPC, IGF2BP2 and YTHDF1 were further validated in four GEO datasets. Moreover, an m6A-based model exhibited moderate accuracy in predicting overall survival in PAAD samples. Additionally, potential m6A modification targets were screened by selecting genes from a set of 23,391 genes that not only harbored the most m6A-modified sites but also showed a robust correlation with PAAD survival. Moreover, we correlated the expression level of m6A-related genes with the immune microenvironment of pancreatic cancer for the first time. Specifically, both arm-level gain and deletion of ALKBH5 decreased the infiltration of CD8+T cells (P <0:05 and P <0:01, respectively). Conclusion. Collectively, our findings suggest a novel anticancer strategy for restoring balanced RNA methylation in tumor cells and guide clinical physicians in developing a new practical approach for considering the impact of related genes on prognosis.
Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers

Rui Li,Yun-Hong Yin,Xiu-Li Ji,Xiao Liu,Jian-Ping Li,Yi-Qing Qu

DOI: https://doi.org/10.3389/fmolb.2021.644620

IF: 6.113

2021-06-04

Frontiers in Molecular Biosciences

Abstract:N6-methyladenosine RNA modification plays a significant role in the progression of multiple tumorigenesis. Our study identified the imperative role of m6A regulators in the tumor immune microenvironment, survival, stemness score, and anticancer drug sensitivity of pan-cancer. The Wilcox test was to identify the differential expression between 17 m6A regulators across 33 TCGA cancer types and their normal tissues from UCSC Xena GDC pan-cancer. Survival analysis of m6A-related regulators in 33 TCGA cancer types was identified using the “survival” and “survminer” package. The Spearman correlation test and Pearson correlation test were used to identify the correlation relationship between m6A regulators expression and tumor microenvironment, tumor stem cell score, and drug sensitivity of anticancer drugs. ConsensusPathDB was used for exploring m6A regulators functional enrichment. The 17 (METTL3, WTAP, METTL14, RBM15, RBM15B, VIRMA, HNRNPC, HNRNPA2B1, YTHDC1, ZC3H13, YTHDF1, YTHDC2, YTHDF2, IGF2BP3, IGF2BP1, FTO, and ALKBH5) m6A regulators were differentially expressed in 18 TCGA cancer types and adjacent normal tissues. Correlation analysis indicated that the relationship between the expression of 17 m6A regulators and tumor microenvironment indicated that the higher expression of m6A regulators, the higher the degree of tumor stem cells. The anticancer drug sensitivity analysis indicated that ZC3H13 expression had a positive relationship with anticancer drugs such as selumetinib, dabrafenib, cobimetinib, trametinib, and hypothemycin ( p < 0.001). YTHDF2 expression was significantly negatively correlated with the anticancer drug dasatinib ( p < 0.001). The pan-cancer immune subtype analysis showed that the 17 m6A regulators were significantly different in immune subtype C1 (wound healing), C3 (inflammatory), C2 (IFN-gamma dominant), C5 (immunological quiet), C4 (lymphocyte depleted), and C6 (TGF-beta dominant) ( p < 0.001). Our study provides a comprehensive insight for revealing the significant role of m6A regulators in the tumor immune microenvironment, stemness score, and anticancer drug sensitivity of human cancers.

biochemistry & molecular biology
An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer

Zhijun Zhou,Junxia Zhang,Chao Xu,Jingxuan Yang,Yuqing Zhang,Mingyang Liu,Xiuhui Shi,Xiaoping Li,Hanxiang Zhan,Wei Chen,Lacey R. McNally,Kar-Ming Fung,Wenyi Luo,Courtney W. Houchen,Yulong He,Changhua Zhang,Min Li

DOI: https://doi.org/10.1016/j.ebiom.2021.103271

IF: 11.205

2021-03-01

EBioMedicine

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>N6-methyladenosine (m6A) is the most abundant mRNA modification. Whether m6A regulators can determine tumor aggressiveness and risk of immune evasion in pancreatic ductal adenocarcinoma (PDAC) remains unknown.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>An integrated model named "m6Ascore" is constructed based on RNA-seq data of m6A regulators in PDAC. Association of m6Ascore and overall survival is validated across several different datasets. Overlaps of m6Ascore and established molecular classifications of PDAC is examined. Immune infiltration, enriched pathways, somatic copy number alterations (SCNAs), mutation profiles and response to immune checkpoint inhibitors are compared between m6Ascore-high and m6Ascore-low tumors.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>m6Ascore is associated with dismal overall survival and increased tumor recurrence in PDAC as well as several other solid tumors including colorectal cancer and breast cancer. Basal-like (Squamous) PDAC has higher m6Ascore than that in the classical PDAC. Mechanism study showed m6Ascore-high tumors are characterized with reduced immune infiltration and T cells exhaustion. Meanwhile, m6Ascore is associated with genes regulating cachexia and chemoresistance in PDAC. Furthermore, distinct SCNAs patterns and mutation profiles of <em>KRAS</em> and <em>TP</em>53 are present in m6Ascore-high tumors, indicating immune evasion. m6Ascore-low tumors have higher response rates to immune checkpoint inhibitors (ICIs).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>These findings indicate m6Ascore can predict aggressiveness and immune evasion in pancreatic cancer. This model has implications for pancreatic cancer prognosis and treatment response to ICIs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>This work was supported in part by National Institutes of Health (NIH) grants to M. Li (R01 CA186338, R01 CA203108, R01 CA247234 and the William and Ella Owens Medical Research Foundation) and NIH/National Cancer Institute Q39 award P30CA225520 to Stephenson Cancer Center.</p>

medicine, research & experimental
Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer

Ying Ye,Weiyi Feng,Jialiang Zhang,Kaiyu Zhu,Xudong Huang,Ling Pan,Jiachun Su,Yanfen Zheng,Rui Li,Shuang Deng,Ruihong Bai,Lisha Zhuang,Lusheng Wei,Junge Deng,Mei Li,Rufu Chen,Dongxin Lin,Zhixiang Zuo,Jian Zheng

DOI: https://doi.org/10.1186/s13073-021-01002-w

IF: 15.266

2021-11-19

Genome Medicine

Abstract:Abstract Background N 6 -methyladenosine (m 6 A) is the most abundant modification of RNA in eukaryotic cells and play critical roles in cancer. While most related studies focus on m 6 A modifications in linear RNA, transcriptome-wide profiling and exploration of m 6 A modification in circular RNAs in cancer is still lacking. Methods For the detection of m 6 A modification in circRNAs, we developed a new bioinformatics tools called Circm6A and applied it to the m 6 A-seq data of 77 tissue samples from 58 individuals with pancreatic ductal adenocarcinoma (PDAC). Results Circm6A performs better than the existing circRNA identification tools, which achieved highest F1 score among these tools in the detection of circRNAs with m 6 A modifications. By using Circm6A, we identified a total of 8807 m 6 A-circRNAs from our m 6 A-seq data. The m 6 A-circRNAs tend to be hypermethylated in PDAC tumor tissues compared with normal tissues. The hypermethylated m 6 A-circRNAs were associated with a significant gain of circRNA-mRNA coexpression network, leading to the dysregulation of many important cancer-related pathways. Moreover, we found the cues that hypermethylated m 6 A-circRNAs may promote the circularization and translation of circRNAs. Conclusions These comprehensive findings further bridged the knowledge gaps between m 6 A modification and circRNAs fields by depicting the m 6 A-circRNAs genomic landscape of PDAC patients and revealed the emerging roles played by m 6 A-circRNAs in pancreatic cancer. Circm6A is available at https://github.com/canceromics/circm6a .

genetics & heredity
Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes

Weidong Sun,Yingchao Su,Zhiqiang Zhang

DOI: https://doi.org/10.1007/s12672-024-01298-1

2024-09-18

Abstract:Background: The study aims to comprehensively combine colorectal cancer data cohorts in order to analyze the effects of various DNA methylation-coding genes on colorectal cancer patients. The annual incidence and mortality of colorectal cancer are very high, and there are no effective treatments for advanced colorectal cancer. DNA methylation is a method widely used to regulate epigenetics in the molecular mechanism study of tumors. Method: Three single-cell cohorts GSE166555, GSE146771, and EMTAB8107, and five transcriptome cohorts GSE17536, GSE39582, GSE72970, and TCGA-CRC (TCGA-COAD and TCGA-READ) were applied in this study. 2 erasers (ALKBH5 and FTO), There are 7 writers (METTL3, METTL14, WTAP, VIRMA, RBM15, RBM15B, and ZC3H13) and 11 readers (YTHDC1, IGF2BP1, IGF2BP2, IGF2BP3, YTHDF1, YTHDF3, YTHDC2, and HNRNPA2B1, YTHDF2, HNRNPC and RBMX), a total of 20 M6A regulators, were used as the basis of the dataset in this study and were applied to the construction of molecular typing and prognostic models. Drugs that are differentially sensitive in methylation-regulated gene-related prognostic models were identified using the ConsensusClusterPlus package, which was also used to identify distinct methylation regulatory expression patterns in colorectal cancer and to model the relationship between tissue gene expression profiles and drug IC50 values. Finally, TISCH2 assessed which immune cells were significantly expressed with M6A scores. The immunosuppression of M6A methylation is spatially explained. Results: This study used data from 583 CRC patients in the TCGA-CRC cohort. Firstly, the mutation frequency and CNV variation frequency of 20 m6A modification-related factors were analyzed, and the corresponding histogram and heat map were drawn. The study next analyzed the expression variations between mutant and wild forms of the VIRMA gene and explored differences in the expression of these variables in tumor and normal tissues. In addition, the samples were divided into different subgroups by molecular clustering method based on m6A modification, and each subgroup's expression and clinicopathological characteristics were analyzed. Finally, we compared prognostic differences, tumor microenvironment (TME) characteristics, immune cell infiltration, and gene function enrichment among different subpopulations. We also developed a colorectal cancer m6A-associated gene signature and validated its prognostic effects across multiple cohorts. Finally, using single-cell RNA sequencing data, we confirmed that tumor cells show elevated expression of m6A-related gene signatures. Discussion: This study explored the mutation frequency, expression differences, interactions, molecular clustering, prognostic effect, and association with tumor characteristics of m6A modification-related factors in CRC and validated them at the single-cell level. These results clarify the association between m6A alteration and colorectal cancer (CRC) and offer important insights into the molecular recognition and management of cancer.
Identification of genetic variants in m6A modification genes associated with pancreatic cancer risk in the Chinese population

Pingting Ying,Yao Li,Nan Yang,Xiaoyang Wang,Haoxue Wang,Heng He,Bin Li,Xiating Peng,Danyi Zou,Ying Zhu,Rong Zhong,Xiaoping Miao,Jianbo Tian,Jiang Chang

DOI: https://doi.org/10.1007/s00204-021-02978-5

2021-01-21

Archives of Toxicology

Abstract:N6-Methyladenosine (m6A) is the most prevalent modification of RNA in eukaryotes, and is associated with many cellular processes and even the development of cancers. We hypothesized that single-nucleotide polymorphisms (SNPs) in m6A modification genes, including its "writers", "erasers" and "readers", might affect the m6A functions and associate with the susceptibility to pancreatic ductal adenocarcinoma (PDAC). We first conducted a two-stage case–control study in Chinese population to interrogate all SNPs in 22 m6A modification genes. In the discovery stage, a total of 2735 SNPs were genotyped in 980 patients and 1991 controls. Then, the promising SNP was replicated in another independent population consisting of 858 cases and 2084 controls. As a result, we found the rs7495 in 3′UTR of hnRNPC was significantly associated with increased risk of PDAC in both stages (combined odds ratio = 1.22, 95% confidence interval = 1.12–1.32, P = 2.39 × 10–6). To further reveal the biological function of rs7495 and hnRNPC, we performed a series of biochemical experiments. Luciferase reporter assays indicated that rs7495G allele promoted hnRNPC expression through disrupting a putative binding site for has-miR-183-3p. Cell viability assay demonstrated that knockdown of hnRNPC suppressed the proliferation of PDAC cells. RNA-seq analysis suggested that as an m6A "reader", hnRNPC played an important role in RNA biological processes. In conclusion, our findings elucidated that rs7495G could confer higher risk of PDAC via promoting the expression of hnRNPC through a miRNA-mediated manner. These results provided a novel insight into the critical role of m6A modification in tumorigenesis.

toxicology
Transcriptional regulatory networks mediated by abnormal m6A modifications in tumor development

Wenzheng Qu,Xuekun Li

DOI: https://doi.org/10.21203/rs.3.rs-523230/v1

2021-01-01

Abstract:Abstract Background N6-methyladenosine (m6A) is one of the common modifications of transcripts that is regulated by related proteins including writers, readers and erasers. Abnormal m6A modification plays an important role in the process of tumor development. Current approaches for tumor m6A RNA methylation, based on sequencing data from public databases, focus on the comparison of m6A modification regulator expression by RNA-seq data. Results We obtained MeRIP-seq and corresponding RNA-seq data from GEO database to compare and analyze the distributional characteristics of m6A in different types of tumor samples, the differences in m6A modification enrichment, and the regulatory role in gene transcriptional expression level. We found that the enrichment of m6A modification was enhanced in IMPA and GBM tumor samples, but was decreased in METTL3 knockdown tumor cells. Combined with clinical data from the TCGA database, we found that the high expression of DUSP7 significantly affected the overall survival of AML patients and was involved in tumor development through the PIK3R2 protein and MAPK signaling pathways. Conclusion Abnormal m6A modification enrichment in tumor samples leads to dysregulation in the expression of cancer-related genes.
Additional File 4 of LncRNA-PACERR Induces Pro-Tumour Macrophages Via Interacting with Mir-671-3p and M6a-Reader IGF2BP2 in Pancreatic Ductal Adenocarcinoma

Yihao Liu,Minmin Shi,Xingfeng He,Yibo Cao,Pengyi Liu,Fanlu Li,Xiaxing Deng,Chenlei Wen,Qimin Zhan,Zhiwei Xu,Jiancheng Wang,Baofa Sun,Baiyong Shen

DOI: https://doi.org/10.6084/m9.figshare.19728742

2022-01-01

Abstract:Additional file 4. All primer sequences used in the qPCR process.
Identification of m6A modification patterns and RBM15 mediated macrophage phagocytosis in pancreatic cancer: An integrative analysis

Wei Wang,Ying He,Li-Chao Yao,Yan Yuan,Cong Lu,Liang-Kun Xiong,Peng Ma,Yue-Feng Zhang,Kai-Huan Yu,Zhi-Gang Tang

DOI: https://doi.org/10.1016/j.bbadis.2024.167304

Abstract:Pancreatic cancer (PC) responds weakly to conventional immunotherapy. RNA N6-methyladenosine (m6A) modification has an essential role in the immune response, while its potential role in PC tumor microenvironment (TME) immune cell infiltration remains unknown. In this study, we thoroughly assessed the m6A modification patterns of 472 PC samples using 19 m6A regulators, and we systematically correlated these modification patterns with TME immune cell infiltration characteristics. We also created the m6Ascore and evaluated the m6A modification patterns of individual tumors, identified three different m6A modification patterns, and explored the role of the important m6A "writer" RBM15 in the regulation of macrophage function in PC. Two independent PC cohorts confirmed that patients with higher m6Ascore showed significant survival benefit. We verified that knockdown of RBM15 has the ability to inhibit PC growth and to promote macrophage infiltration and enhance phagocytosis of PC cells by macrophages. In conclusion, m6A modifications play a non-negligible role in the formation of TME diversity and complexity in PC. We reveal that inhibition of RBM15 suppresses PC development and modulates macrophage phagocytosis, and provide a more effective immunotherapeutic strategy for PC.
Pan-cancer Analysis Reveals m6A Variation and Cell-specific Regulatory Network in Different Cancer Types

Yao Lin,Jingyi Li,Shuaiyi Liang,Yaxin Chen,Yueqi Li,Yixian Cun,Lei Tian,Yuanli Zhou,Yitong Chen,Jiemei Chu,Hubin Chen,Qiang Luo,Ruili Zheng,Gang Wang,Hao Liang,Ping Cui,Sanqi An

DOI: https://doi.org/10.1093/gpbjnl/qzae052

2024-07-05

Abstract:Abstract As the most abundant messenger RNA (mRNA) modification in mRNA, N 6-methyladenosine (m6A) plays a crucial role in RNA fate, impacting cellular and physiological processes in various tumor types. However, our understanding of the function and role of the m6A methylome in tumor heterogeneity remains limited. Herein, we collected and analyzed m6A methylomes across nine human tissues from 97 m6A sequencing (m6A-seq) and RNA sequencing samples. Our findings demonstrate that m6A exhibits different heterogeneity in most tumor tissues compared to normal tissues, which contributes to the diverse clinical outcomes in different cancer types. We also found that the cancer type-specific m6A level regulated the expression of different cancer-related genes in distinct cancer types. Utilizing a novel and reliable method called “m6A-express”, we predicted m6A-regulated genes and revealed that cancer type-specific m6A-regulated genes contributed to the prognosis, tumor origin, and infiltration level of immune cells in diverse patient populations. Furthermore, we identified cell-specific m6A regulators that regulate cancer-specific m6A and constructed a regulatory network. Experimental validation was performed, confirming that the cell-specific m6A regulator CAPRIN1 controls the m6A level of TP53. Overall, our work reveals the clinical relevance of m6A in various tumor tissues and explains how such heterogeneity is established. These results further suggest the potential of m6A for cancer precision medicine for patients with different cancer types.

genetics & heredity
Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer

Bowen Huang,Jianzhou Liu,Jun Lu,Wenyan Gao,Li Zhou,Feng Tian,Yizhi Wang,Mingjie Luo,Dong Liu,Congyong Xie,Ziyu Xun,Chengxi Liu,Yu Wang,Haibo Ma,Junchao Guo

DOI: https://doi.org/10.3389/fonc.2021.812785

IF: 4.7

2022-01-03

Frontiers in Oncology

Abstract:Pancreatic cancer is a highly malignant tumor with a poor survival prognosis. We attempted to establish a robust prognostic model to elucidate the clinicopathological association between lncRNA, which may lead to poor prognosis by influencing m6A modification, and pancreatic cancer. We investigated the lncRNAs expression level and the prognostic value in 440 PDAC patients and 171 normal tissues from GTEx, TCGA, and ICGC databases. The bioinformatic analysis and statistical analysis were used to illustrate the relationship. We implemented Pearson correlation analysis to explore the m6A-related lncRNAs, univariate Cox regression and Kaplan-Meier methods were performed to identify the seven prognostic lncRNAs signatures. We inputted them in the LASSO Cox regression to establish a prognostic model in the TCGA database, verified in the ICGC database. The AUC of the ROC curve of the training set is 0.887, while the validation set is 0.711. Each patient has calculated a risk score and divided it into low-risk and high-risk subgroups by the median value. Moreover, the model showed a robust prognostic ability in the stratification analysis of different risk subgroups, pathological grades, and recurrence events. We established a ceRNA network between lncRNAs and m6A regulators. Enrichment analysis indicated that malignancy-associated biological function and signaling pathways were enriched in the high-risk subgroup and m6A-related lncRNAs target mRNA. We have even identified small molecule drugs, such as Thapsigargin, Mepacrine, and Ellipticine, that may affect pancreatic cancer progression. We found that seven lncRNAs were highly expressed in tumor patients in the GTEx-TCGA database, and LncRNA CASC19/UCA1/LINC01094/LINC02323 were confirmed in both pancreatic cell lines and FISH relative quantity. We provided a comprehensive aerial view between m6A-related lncRNAs and pancreatic cancer’s clinicopathological characteristics, and performed experiments to verify the robustness of the prognostic model.

oncology
Functional Characteristics of DNA N6-methyladenine Modification Based on Long-Read Sequencing in Pancreatic Cancer.

Dianshuang Zhou,Shiwei Guo,Yangyang Wang,Jiyun Zhao,Honghao Liu,Feiyang Zhou,Yan Huang,Yue Gu,Gang Jin,Yan Zhang

DOI: https://doi.org/10.1093/bfgp/elad021

2024-01-01

Briefings in Functional Genomics

Abstract:Abnormalities of DNA modifications are closely related to the pathogenesis and prognosis of pancreatic cancer. The development of third-generation sequencing technology has brought opportunities for the study of new epigenetic modification in cancer. Here, we screened the N6-methyladenine (6mA) and 5-methylcytosine (5mC) modification in pancreatic cancer based on Oxford Nanopore Technologies sequencing. The 6mA levels were lower compared with 5mC and upregulated in pancreatic cancer. We developed a novel method to define differentially methylated deficient region (DMDR), which overlapped 1319 protein-coding genes in pancreatic cancer. Genes screened by DMDRs were more significantly enriched in the cancer genes compared with the traditional differential methylation method (P < 0.001 versus P = 0.21, hypergeometric test). We then identified a survival-related signature based on DMDRs (DMDRSig) that stratified patients into high- and low-risk groups. Functional enrichment analysis indicated that 891 genes were closely related to alternative splicing. Multi-omics data from the cancer genome atlas showed that these genes were frequently altered in cancer samples. Survival analysis indicated that seven genes with high expression (ADAM9, ADAM10, EPS8, FAM83A, FAM111B, LAMA3 and TES) were significantly associated with poor prognosis. In addition, the distinction for pancreatic cancer subtypes was determined using 46 subtype-specific genes and unsupervised clustering. Overall, our study is the first to explore the molecular characteristics of 6mA modifications in pancreatic cancer, indicating that 6mA has the potential to be a target for future clinical treatment.

Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

A Prognostic Model of M6a-Related Lipid Metabolism-Associated Genes in Pancreatic Adenocarcinoma

Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival

Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer

The Potential Value of M6a RNA Methylation in the Development of Cancers Focus on Malignant Glioma

m<SUP>6</SUP>A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer

Characterization of Modification Patterns, Biological Function, Clinical Implication, and Immune Microenvironment Association of m6A Regulators in Pancreatic Cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma

Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers

An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer

Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer

Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes

Identification of genetic variants in m6A modification genes associated with pancreatic cancer risk in the Chinese population

Transcriptional regulatory networks mediated by abnormal m6A modifications in tumor development

Additional File 4 of LncRNA-PACERR Induces Pro-Tumour Macrophages Via Interacting with Mir-671-3p and M6a-Reader IGF2BP2 in Pancreatic Ductal Adenocarcinoma

Identification of m6A modification patterns and RBM15 mediated macrophage phagocytosis in pancreatic cancer: An integrative analysis

Pan-cancer Analysis Reveals m6A Variation and Cell-specific Regulatory Network in Different Cancer Types

Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer

Functional Characteristics of DNA N6-methyladenine Modification Based on Long-Read Sequencing in Pancreatic Cancer.